U.S., July 18 -- ClinicalTrials.gov registry received information related to the study (NCT07070219) titled 'A Phase 1b/ 2 Study of CTD402 in T-ALL/LBL Patients' on July 07.
Brief Summary: The goal of the TENACITY-01 clinical trial is to learn if CTD402 UCART is safe and effective for relapsed/refractory T-ALL/LBL patients.
Participants with relapsed/refractory T-ALL/LBL over the age of 12 will be eligible to participate.
Participants will receive one infusion of CTD402 on Day 0 and will be evaluated for anti-tumor activity by an independent review committee based on the NCCN criteria for T-ALL and the Lugano 2014 criteria for T-LBL.
Patients will be followed for up to 24 months in this study and will be required to enroll under a separ...